Clarus Ventures, LLC - Q3 2014 holdings

$251 Million is the total value of Clarus Ventures, LLC's 6 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 20.0% .

 Value Shares↓ Weighting
AERI  Aerie Pharmaceuticals Inc.$71,763,000
-16.5%
3,468,4950.0%28.64%
-6.1%
OPHT  Ophthotech Corp$60,526,000
-8.0%
1,554,7440.0%24.15%
+3.4%
NSTG  Nanostring Technologies Inc.$43,316,000
-26.8%
3,959,4400.0%17.28%
-17.8%
OXFD  Oxford Immunotec Global PLC$39,382,000
-9.3%
2,579,0620.0%15.71%
+2.0%
TLOG  TetraLogic Pharmaceuticals Corporation$19,322,000
-29.4%
4,644,7050.0%7.71%
-20.6%
VBIV NewVBI Vaccines Inc$16,305,0004,971,091
+100.0%
6.51%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2014-11-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Nanostring Technologies Inc.20Q3 201860.2%
Sientra Inc.16Q3 201838.2%
Oxford Immunotex Global PLC14Q1 201717.4%
Catabasis Pharmaceuticals Inc.14Q3 201815.3%
VBI Vaccines Inc.10Q3 201811.4%
TetraLogic Pharmaceuticals Corporation9Q4 201512.5%
ESSA Pharma Inc.9Q1 20186.5%
Aerie Pharmaceuticals Inc.7Q4 201530.5%
VBI Vaccines Inc.7Q1 20169.1%
Ophthotech Corp6Q1 201531.5%

View Clarus Ventures, LLC's complete holdings history.

Latest filings
TypeFiled
13F-NT2024-05-15
13F-NT2024-02-14
13F-NT2023-11-14
13F-NT2023-08-14
13F-NT2023-05-15
13F-NT2023-02-14
13F-NT2022-11-14
13F-NT2022-08-15
13F-NT2022-05-16
13F-NT2022-02-14

View Clarus Ventures, LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (250615000.0 != 250614000.0)

Export Clarus Ventures, LLC's holdings